Providers caution against overly broad enforcement as CMS pursues new Medicare disenrollment avenues
Provisions proposed in the 2027 Home Health payment rule would give the agency the right to revoke enrollment in the Medicare ...
The next major Medicare risk for spine and orthopedic practices may not begin with a denied surgical claim. It may begin with the enrollment file. CMS’ July 1 proposed rule is formally a home health ...
The Centers for Medicare & Medicaid Services July 1 issued its calendar year 2027 proposed rule for the home health prospective payment system. The rule proposes a 2.4% update, which includes a 3.1% ...
CMS launches Medicare GLP-1 Bridge to offer select beneficiaries fixed-cost access to GLP-1 drugs from July 2026 through 2027.
CMS said June 12 it seeks to shift the Medicare Drug Price Negotiation Program from guidance-based administration to codified regulation. Here is what hospital and health system leaders need to know.
CHARLOTTE — Atrium Health is working with Charlotte-Mecklenburg Schools to help tackle a statewide shortage of healthcare workers. The paid internship program is made possible through a partnership ...
The Trump administration has authorized a test program to see if the cannabis compound can ease some symptoms and reduce health care costs among older patients. By Jan Hoffman The Trump administration ...
"We continue to make progress against our top priorities of maintaining strong margins, reducing our cost structure and moving the business towards sustainable profitability," said CEO, Secretary & ...
Jeneen Iwugo, right, acting director of CMS's Center for Program Integrity, and Sarah Harvey, left, director of the GAO's Science & Technology Assessment division, participate in a panel discussion at ...
A financially sustainable solution for how to cover GLP-1 drugs for obesity remains elusive. The Centers for Medicare & Medicaid Services (CMS) has announced that its temporary program to cover GLP-1 ...
The Centers for Medicare & Medicaid Services (CMS) has announced that its temporary program to cover GLP-1 drugs for obesity in Medicare, called the BALANCE model, will not launch as scheduled on Jan.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results